Lisinopril vs Losartan Head-to-Head Efficacy: What the Trials Actually Show

Why Comparing These Two Drugs Is Harder Than It Looks

There is no single head-to-head randomized controlled trial of adequate power that enrolled patients to receive either lisinopril or losartan as the sole comparison. Both belong to the renin-angiotensin-aldosterone system (RAAS) blocking drug family, and they share a mechanism up to the point of angiotensin II production. Beyond that point, their pharmacology diverges.

How Each Drug Works

Lisinopril blocks angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II. This also prevents ACE from breaking down bradykinin, which accumulates and causes the characteristic dry cough in 10-15% of patients.

Losartan blocks the AT1 receptor directly. Angiotensin II is still produced, but it cannot bind its primary receptor. Bradykinin is unaffected, which explains why cough rates with losartan are close to placebo rates in clinical trials.

The Evidence Gap

Because no definitive head-to-head trial exists, clinicians must synthesize data from trials that compared each agent against a common control (usually chlorthalidone, atenolol, or placebo) and from smaller comparative studies. This approach has real limitations: patient populations, follow-up durations, and background therapies differ across trials. The comparisons in this article are cross-trial inferences, not direct randomized comparisons, and should be interpreted accordingly.

ALLHAT: The Largest Trial Informing Lisinopril's Cardiovascular Profile

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) remains the largest hypertension outcomes trial ever conducted. It enrolled 33,357 high-risk hypertensive patients at least 55 years old and randomly assigned them to chlorthalidone, amlodipine, or lisinopril over a mean follow-up of 4.9 years. [1]

Primary Outcome: Fatal CHD and Non-Fatal MI

For the primary endpoint of combined fatal coronary heart disease and non-fatal myocardial infarction, lisinopril performed statistically equivalently to chlorthalidone (relative risk 0.99, 95% CI 0.91-1.08). That finding reassured clinicians that RAAS blockade is a legitimate first-line strategy for high-risk hypertensive patients.

Where Lisinopril Fell Short in ALLHAT

The secondary outcomes told a more nuanced story. Lisinopril was associated with a significantly higher rate of stroke compared with chlorthalidone (relative risk 1.15, 95% CI 1.02-1.30, P<0.02), driven substantially by worse blood pressure control in the lisinopril arm, particularly in Black patients. [1]

The trial's investigators noted that in Black participants, chlorthalidone produced meaningfully better blood pressure reductions than lisinopril, and that difference likely explains much of the stroke signal. The American College of Cardiology and American Heart Association (ACC/AHA) 2017 hypertension guidelines reflect this finding by recommending thiazide-type diuretics or calcium channel blockers as preferred first-line agents in Black patients without proteinuric CKD. [2]

Heart Failure Signal

ALLHAT also found that combined fatal and non-fatal heart failure was more common in the lisinopril arm than in the chlorthalidone arm (RR 1.19, 95% CI 1.07-1.31). Chlorthalidone's volume-reducing effect likely explains this difference rather than any harm from lisinopril itself. When compared with amlodipine, lisinopril actually showed a lower heart failure rate, which aligns with the known benefit of RAAS blockade over calcium channel blockers for heart failure prevention.

LIFE: The Landmark Trial Behind Losartan's Profile

LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) enrolled 9,193 patients with hypertension and electrocardiographic left ventricular hypertrophy (LVH), randomly assigning them to losartan 50-100 mg daily or atenolol 50-100 mg daily over a mean follow-up of 4.8 years. [3]

Primary Composite Endpoint

Losartan reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol (RR 0.87, 95% CI 0.77-0.98, P<0.021), with most of the benefit driven by a 25% reduction in fatal and non-fatal stroke (RR 0.75, 95% CI 0.63-0.89, P<0.001). [3] Blood pressure control was nearly identical between the two arms, suggesting the stroke benefit was at least partly blood-pressure-independent.

LVH Regression

Losartan produced significantly greater regression of electrocardiographic LVH than atenolol. LVH is an independent predictor of CV events, and its regression with losartan correlated with better outcomes. This benefit is thought to reflect the specific effect of AT1 receptor blockade on cardiac remodeling rather than blood pressure reduction alone.

The LIFE Diabetic Subgroup

In the 1,195 patients with diabetes in LIFE, losartan produced a 37% reduction in the primary composite endpoint compared with atenolol (P<0.002), along with a 39% reduction in cardiovascular mortality. [3] The new-onset diabetes rate was also 25% lower with losartan than with atenolol, though that comparison is of limited applicability when choosing between losartan and lisinopril, since both RAAS agents reduce new-onset diabetes risk compared with thiazides and beta-blockers.

Blood Pressure Lowering Efficacy: Dose-by-Dose Comparison

Standard Doses and Expected Reductions

At its most commonly prescribed dose of 10-40 mg daily, lisinopril typically lowers systolic blood pressure by 10-12 mmHg and diastolic BP by 6-8 mmHg in patients with stage 1-2 hypertension. Losartan at 50-100 mg daily produces comparable reductions: a 2003 meta-analysis of 354 double-blind trials published in the American Journal of Hypertension found that the two drug classes, ACE inhibitors and ARBs, produced nearly identical 24-hour ambulatory blood pressure reductions when analyzed at guideline-recommended doses. [4]

Trough-to-Peak Ratio

Losartan has a relatively short half-life of about 2 hours, but its active metabolite EXP3174 has a half-life of 6-9 hours. This metabolite is 10-40 times more potent as an AT1 blocker than losartan itself. The trough-to-peak ratio for the combination remains adequate for once-daily dosing, though some patients may achieve better 24-hour control with twice-daily dosing or by switching to a longer-acting ARB such as olmesartan or telmisartan.

Lisinopril's half-life is approximately 12 hours, which generally supports more consistent 24-hour coverage on once-daily dosing.

Combination with Hydrochlorothiazide

Both drugs are available in fixed-dose combinations with hydrochlorothiazide (HCTZ): lisinopril/HCTZ and losartan/HCTZ (sold under the brand name Hyzaar). The additive blood pressure reduction from combining either RAAS blocker with a thiazide is typically an additional 5-8 mmHg systolic.

Kidney Protection: CKD and Diabetic Nephropathy

Both lisinopril and losartan carry strong evidence for slowing the progression of diabetic kidney disease, though the key studies were not head-to-head trials.

Lisinopril in Type 1 Diabetic Nephropathy

The landmark Lewis et al. Trial (NEJM 1993, N=409) showed that lisinopril reduced the risk of doubling of serum creatinine by 48% and reduced the combined endpoint of doubling of creatinine, end-stage renal disease, or death by 50% in patients with type 1 diabetes and nephropathy, compared with placebo. [5] Blood pressure reduction in the placebo arm was matched using other antihypertensives, implying the benefit was at least partially independent of blood pressure control.

Losartan in Type 2 Diabetic Nephropathy

RENAAL (NEJM 2001, N=1,513) established losartan's renal benefit in type 2 diabetes. Losartan 100 mg daily reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% compared with placebo (P<0.02), and reduced ESRD alone by 28% (P<0.002). [6] The IDNT trial (NEJM 2001, N=1,715) similarly showed irbesartan (another ARB) outperformed amlodipine and placebo for renal endpoints in type 2 diabetic nephropathy, though IDNT was not a direct comparison with an ACE inhibitor. [7]

Which Agent to Choose for CKD

The 2022 KDIGO Clinical Practice Guideline for Diabetes Management in CKD recommends either an ACE inhibitor or ARB as first-line therapy for patients with diabetes and CKD with elevated urine albumin-to-creatinine ratio (uACR >30 mg/g). [8] The guideline does not rank one class over the other for renal outcomes. Combining an ACE inhibitor with an ARB is explicitly not recommended given the ONTARGET finding (NEJM 2008) that dual RAAS blockade increased adverse renal events without improving cardiovascular outcomes.

The HealthRX clinical team uses a three-factor decision framework when choosing between lisinopril and losartan for a given patient:

1. Cough history. Any patient who has experienced ACE-inhibitor-induced cough on lisinopril or another ACE inhibitor should receive losartan or a different ARB, not an ACE inhibitor rechallenge.
2. Diabetes type. Type 1 diabetic nephropathy has the strongest evidence base for ACE inhibitors (Lewis et al., NEJM 1993). Type 2 diabetic nephropathy has guideline-level evidence for ARBs from RENAAL and IDNT. In practice, both classes are acceptable for either type by current KDIGO guidance.
3. Ethnicity and stroke risk. ALLHAT found worse stroke outcomes with lisinopril than with chlorthalidone, particularly in Black patients. In a Black patient without CKD or proteinuria, thiazide-type diuretics or CCBs are preferred first-line per ACC/AHA 2017 guidelines. If RAAS blockade is needed for nephropathy, losartan is a reasonable choice given its stroke reduction data from LIFE.

Heart Failure: Where ACE Inhibitors Have a Longer Track Record

Established Evidence for Lisinopril

ACE inhibitors have been used in heart failure with reduced ejection fraction (HFrEF) since the early 1990s. CONSENSUS (NEJM 1987) showed enalapril reduced mortality by 40% in NYHA class IV heart failure. SOLVD (NEJM 1991) demonstrated enalapril reduced mortality and hospitalization in patients with ejection fraction <35%. [9] These trials used enalapril, not lisinopril, but the mortality benefit is considered a class effect by the ACC/AHA Heart Failure Guidelines.

Lisinopril itself was studied in ATLAS (1999, N=3,164), which found that high-dose lisinopril (32.5-35 mg daily) was superior to low-dose lisinopril (2.5-5 mg daily) for reducing the composite of all-cause mortality and hospitalization by 12% (P<0.002).

Losartan's Role in Heart Failure

Losartan was studied in ELITE II (Lancet 2000, N=3,152), which found that losartan did not produce superior survival compared with captopril in elderly heart failure patients. [10] This trial effectively shifted ARBs into a second-line role for HFrEF, reserved primarily for patients intolerant of ACE inhibitors due to cough or angioedema.

The 2022 AHA/ACC/HFSA Heart Failure Guideline gives ACE inhibitors and ARBs the same Class I, Level A recommendation for HFrEF with EF <40%, but notes ARBs are appropriate primarily when ACE inhibitors are not tolerated. [11]

Tolerability and Side Effects

Dry Cough

Dry cough is the most common reason patients switch from lisinopril to losartan. ACE-inhibitor-induced cough occurs in 10-15% of white patients and in up to 30-40% of Asian patients, reflecting pharmacogenomic differences in bradykinin degradation pathways. Losartan produces cough at rates statistically indistinguishable from placebo in clinical trials.

Angioedema

Angioedema affects approximately 0.1-0.7% of patients on ACE inhibitors. Black patients face a 3- to 5-fold higher risk than white patients. Angioedema is potentially life-threatening. Any patient with a history of ACE-inhibitor-induced angioedema should not receive another ACE inhibitor and should be transitioned to an ARB with a minimum washout period of several weeks, given that some cases of angioedema have been reported in ARB users who previously had ACE-inhibitor-induced angioedema (estimated cross-reactivity rate around 8-17%).

Hyperkalemia

Both drug classes can raise serum potassium by reducing aldosterone-mediated potassium excretion. The risk is higher in patients with CKD, diabetes, or concurrent use of potassium-sparing diuretics. Routine monitoring of serum potassium and creatinine is required at baseline, at 2-4 weeks after initiation or dose change, and periodically thereafter.

Teratogenicity

Both agents are absolutely contraindicated during pregnancy. Exposure during the second or third trimester is associated with fetal renal tubular dysplasia, oligohydramnios, neonatal renal failure, and fetal death. Women of childbearing age should be counseled on this risk before starting either drug and should use effective contraception.

Can You Switch from Lisinopril to Losartan?

Switching is common, clinically safe, and well-supported by practice guidelines. The most frequent clinical scenario is a patient on lisinopril who develops a persistent dry cough that does not resolve after 4-8 weeks. Cough resolves in most patients within 1-4 weeks of stopping lisinopril.

How to Switch

The transition can generally be made directly, without a washout period, unless angioedema was the reason for stopping. When angioedema is involved, a minimum 6-week washout is prudent before starting an ARB, and some clinicians extend this to 12 weeks given reports of late ARB-associated angioedema in ACE-inhibitor-sensitized patients.

When switching for cough, a reasonable approach is to stop lisinopril on a given day and start losartan 50 mg the following morning. Blood pressure should be rechecked within 2 weeks of the switch. Most patients maintain equivalent or better blood pressure control after the transition, since ARBs and ACE inhibitors produce comparable blood pressure reductions at equivalent doses.

Dose Equivalence

There is no universally agreed upon milligram-to-milligram equivalence between lisinopril and losartan. A practical starting point used in many clinical settings: lisinopril 10 mg daily corresponds roughly to losartan 50 mg daily, and lisinopril 20-40 mg daily to losartan 100 mg daily. These are not pharmacokinetically derived equivalences; they reflect titration targets from registration trials and should be individualized based on blood pressure response.

Current Guideline Positioning

The ACC/AHA 2017 Hypertension Guideline (updated in the 2023 AHA scientific statement on hypertension) does not rank ACE inhibitors above ARBs or vice versa for most patients. Both classes receive the same recommendation tier for hypertension with compelling indications including CKD, diabetes, and post-MI with reduced ejection fraction. [2]

The European Society of Cardiology (ESC) 2023 guidelines similarly treat the two classes as interchangeable for most indications, with individual patient factors (tolerability, cost, co-morbidity profile) driving the final choice.

As the ACC/AHA 2017 guideline document states: "ACE inhibitors or ARBs are recommended in adults with hypertension and CKD to slow kidney disease progression... These drug classes are not recommended for use in combination." [2]

A Practical Decision Summary

Patients with type 1 diabetic nephropathy, heart failure with reduced EF, or post-MI LV dysfunction have the longest track record with ACE inhibitors including lisinopril. Patients with type 2 diabetic nephropathy and proteinuria have strong ARB-specific trial data from RENAAL. Patients who develop cough on lisinopril should move to losartan. Patients with a history of ACE-inhibitor-induced angioedema require careful evaluation before any ARB is started.

The blood pressure lowering efficacy of the two agents is equivalent at standard doses. The cardiovascular outcome data, while not from a direct head-to-head trial, shows similar event reduction rates across major trials after accounting for the different comparator arms and patient populations used in ALLHAT and LIFE.

For most patients, the practical difference between these two drugs comes down to tolerability. Patients who tolerate both can stay on whichever was started first. Patients on lisinopril with cough should be switched to losartan 50-100 mg. The usual follow-up target is a systolic blood pressure below 130 mmHg in most adults per the ACC/AHA 2017 threshold, checked at 1 month after any initiation or dose adjustment.